Skip to main content

FACTORES PREDICTORES, NUEVOS BIOMARCADORES Y ANTICUERPOS INVOLUCRADOS EN ENFERMEDADES DESMIELINIZANTES INFANTILES

PI21/00316

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Execution centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders

  • Fonseca, Elianet Gisell|||0000-0002-3613-3185
  • Olive Cirera, Gemma
  • Chen, Li Wen|||0000-0002-4013-8333
  • Paredes-Carmona, Fernando
  • Vázquez-López, Mara|||0000-0002-1599-8841
  • Felipe-Rucián, Ana|||0000-0002-5267-1370
  • Romeu, Gemma
  • Martínez Hernández, Eugenia
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Sepulveda, Maria
  • Saiz, Albert|||0000-0002-5793-8791
  • Dalmau, Josep|||0000-0001-5856-2813
  • Armangue, Thais|||0000-0001-6192-6171
  • Nuñez Enamorado, Noem
  • Boyero Duran, Sabas
  • Mendibe-Bilbao, María del Mar
  • Visa-Reñé, Nuria
ObjectivesThe aim of this study was to report the clinical features, disease-modifying treatment (DMT) response, and outcomes of children with MOG-IgG who fulfill the 2017 McDonald criteria for multiple sclerosis (MS).MethodsThis prospective observational study included children (<18 years) with a suspected acquired demyelinating syndrome (ADS) whose serum or CSF was positive for MOG-IgG, who met the indicated MS criteria, and who had ≥1 year of clinical follow-up. MOG-IgG was tested using live cell-based assays.ResultsOf 554 children with confirmed ADS (196 with MOG-IgG), 8 (median age 11 years, interquartile range 9-14) harbored MOG-IgG and fulfilled MS criteria: 2 had typical MS and 6 had overlapping MOGAD-MS features at onset, but 5 of the latter group developed an MS-like course during follow-up. Five of 7 patients with assessable samples were Epstein-Barr virus seropositive at disease onset, and all 8 had persistent silent radiologic activity with lesional location and morphology suggestive of MS, leading to initiation of DMT. All initial treatments were well tolerated, but eventually, 7 of 8 children (88%) required high-efficacy DMT.DiscussionIn this pediatric cohort, 4% of patients with MOG-IgG met criteria for MS. The clinical-radiologic spectrum ranged from typical MS to overlapping MOGAD-MS, and patients usually required high-efficacy DMT.